Tazeen Ahmad

“So, Yen, I wanted to get your thoughts about the IT challenge on UVL. We know, obviously, what the blue sky scenario is for Ascendus, and, you know, most of the scenarios look positive, but can you just maybe walk us through what the potential outcomes are?”

“When they do, what should we be thinking about in terms of readout or read through rather for FISERA? Thanks.”

“I think that's an exciting potential next big drug for you guys. Wanted to understand what you're hoping to learn from the healthy volunteer data that you're expected to show in the fourth quarter, especially since you've already picked lupus to move into phase 1B there.”

“To clarify, do you expect the discontinuation rate to change with the six formulations? And then secondly, on pricing in Europe for debut, on average, what percent discount do you think you'll have to take in the major European countries over time?”

“Are you still planning on sharing a phase two update for your alpha 4 beta 7 program in IBD? And if you are, what level of data should we expect to see there? And how could it differentiate from other programs that are looking at the same indication using the similar mechanism?”